Moving toward safer AAV manufacturing: Evaluation of synthetic DNA as an alternative to plasmid DNA

image with purple to pink gradient with three pages of an AAV whitepaper in the middle about synthetic DNA as a safer alternative to plasmid dna

As AAV-based gene therapies move toward broader clinical adoption, the safety of viral vector manufacturing has come under increasing focus. Growing evidence of plasmid-derived DNA impurities in rAAV products, combined with heightened regulatory expectations around product quality and patient safety, is driving the industry to re-evaluate traditional plasmid DNA-based manufacturing approaches.

This whitepaper explores the limitations of plasmid DNA as a starting material for AAV manufacturing and examines the need for safer, more controlled alternatives. Learn how advances in synthetic DNA technologies are enabling the production of high-quality AAV vectors while reducing the risks associated with bacterial-derived impurities, supporting the development of safer and more consistent gene therapies.

Download our whitepaper to learn about how synthetic DNA can improve AAV manufacturing:

Reduction of bacterial backbone-related impurities being incorporated into the final AAV product
Improved efficiency and cost-effectiveness when using synthetic DNA as starting material for AAV manufacturing
Achieve high transfection with less DNA mass required compared to plasmid DNA

Download whitepaper now